WINNIPEG, Manitoba, Oct. 25, 2023 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it will be unveiling the new brand for its coactiv+™ Antimicrobial Wound Gel product (“Wound Gel”) at the Symposium on Advanced Wound Care Fall forum (“SAWC Fall”).
Both Kane Biotech and its U.S. Wound Gel distribution partner, ProgenaCare Global, will host informational booths at SAWC Fall introducing the new brand and recruiting practitioners to participate in clinical evaluations using the Company’s Wound Gel.
“I’m excited to be introducing the new brand to investors and practitioners. Kane and ProgenaCare worked closely together on the branding and have come up with a result I’m very proud of. Also, we’ve been working diligently to manufacture a limited quantity of product in-house which will allow us to get some clinical evaluations underway as we scale up manufacturing,” stated Marc Edwards, President and CEO of Kane Biotech.
Kane will also present a technology poster on Kane’s Wound Gel which is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic Pluronic surfactant with thermo-gelling properties. The combination of these three components provides for a moist environment in an easy-to-use gel that is optimized for sensitive wounds.
The conference will take place from November 2-5, 2023, in Las Vegas, Nevada and is intended to connect the entire wound care community fostering inclusivity, innovation and interdisciplinary collaboration. During this conference, Kane Biotech will present along with other important voices in Biotech and Wound Care.
About ProgenaCare (ProgenaCare Global LLC)
ProgenaCare is a purpose-driven medical device company leveraging cutting-edge advances in biomaterials and medical device technologies to provide effective, affordable advanced wound care solutions to patients across the socioeconomic spectrum and around the world.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.
|For more information:|
|Marc Edwards||Ray Dupuis|
|Chief Executive Officer||Chief Financial Officer|
|Kane Biotech Inc.||Kane Biotech Inc.|
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.